About us

IsomAb is a Nottingham and Cambridge, UK- based biotechnology company developing isoform specific antibodies for ischaemic disease. Founded in 2022, the Company is a spin-out from the University of Nottingham; early research was conducted at the University of Bristol and research funding has been received from the British Heart Foundation, Wellcome Trust and the Medical Research Council.

The Company is led by a highly experienced management team, and has a strong scientific foundation, with multi-disciplinary experience in antibody development and manufacture.

The Company is supported by an international Clinical Advisory Board comprising renowned vascular surgeons and diabetologists.

Our Investors are focused in the biotech and technology sectors with a real-world understanding of the challenges and provide valuable strategic advice.